+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

L

Actively Recruiting

Researchers are studying the long-term safety and tolerability of KarXT for treating mania or mania with mixed features in adults with Bipolar-I disorder. This phase 3 open-label extension trial focuses on participants who have either completed prior related studies or are newly diagnosed with specific criteria. The study aims to monitor adverse events and changes in symptoms over an extended period. Participants receive KarXT at specified doses, with some possibly receiving additional therapeutic doses of Lithium, Valproate, or Lamotrigine. The study does not involve placebo and is designed as a single-group intervention. The treatment and monitoring continue for up to 54 weeks, focusing on safety and symptom assessments. During the study, participants undergo regular evaluations including psychiatric assessments and safety monitoring. Researchers track treatment-emergent adverse events, serious adverse events, and changes in suicidal ideation using the Columbia-Suicide Severity Rating Scale. Additional assessments include rating scales for movement disorders and urinary symptoms. The total participation period extends up to about one year, with ongoing safety and tolerability evaluations.

Age: 18Years - 65YearsAll GendersPhase 3
184 locations
E

Actively Recruiting

Researchers are conducting a Phase 3, randomized, double-blind, placebo-controlled study to evaluate KarXT in adults with Bipolar-I disorder experiencing acute manic or mixed episodes. The study focuses on assessing how well KarXT works compared to a placebo during a three-week inpatient treatment period. Participants must be hospitalized due to their acute symptoms, and the study includes a total duration of up to seven weeks covering screening, treatment, and safety follow-up. Participants are randomly assigned to receive either KarXT or a placebo with flexible dosing during the inpatient phase. The main goal is to observe changes in manic symptoms using the Young Mania Rating Scale over three weeks. The study monitors safety and efficacy through standardized psychiatric assessments and follows participants closely during the inpatient stay. During the trial, participants will undergo regular evaluations including psychiatric ratings and clinical global impressions to track symptom changes and treatment response. The study includes initial screening, a three-week double-blind treatment period while hospitalized, and a safety follow-up period to monitor participants health. The total participation time does not exceed seven weeks.

Age: 18Years - 65YearsAll GendersPhase 3
85 locations
S

Actively Recruiting

Researchers are evaluating the pharmacokinetics, safety, tolerability, and efficacy of a once-a-month, long-acting subcutaneous injection of Cariprazine Depot in adults eligible for oral Cariprazine treatment. This study involves subjects diagnosed with schizophrenia, bipolar I disorder, or major depressive disorder, focusing on those who are clinically stable or antipsychotic-naive, depending on the cohort. The research is conducted as an open-label, multi-center Phase IIIa trial sponsored by Mapi Pharma Ltd. Participants will receive escalating doses of Cariprazine Depot across three cohorts. Cohorts 1 and 2 receive single doses of 22 mg or 44 mg, respectively, while cohort 3 receives three monthly doses of the maximum tolerated dose MTD. Additionally, oral Cariprazine at 3 mgday is administered for three months for comparison. The study is non-randomized and open-label, with no masking, to assess dose effects and treatment responses. During the study, participants will be monitored for adverse events, injection site reactions, and plasma levels of Cariprazine and its metabolites over 22 to 24 weeks. The efficacy in cohort 3 will be evaluated using symptom scores such as the Positive and Negative Symptom Score PANSS and Clinical Global Impression Scale CGI. Safety and tolerability assessments are conducted throughout, with the study duration extending up to 24 weeks per participant.

Age: 18Years - 64YearsAll GendersPhase 1Phase 2
6 locations